EGFR and PTEN Gene Mutation Status in Glioblastoma Patients and their Prognostic Impact on Patient's SurvivalSajad Hussain Arif1ψ*, Arshad A. Pandith2ψ, Abdul Rashid Bhat1, Altaf Umar Ramzan1, Nayil Khursheed Malik1, Sarabjit S. Chibber1, Abrar A. Wani1, Rehana Tabasum3 and Altaf Kirmani1
- *Corresponding Author:
- Sajad Hussain Arif
Department of Neurosurgery
Sher-I-Kashmir Institute of Medical Sciences
Soura, Srinagar 190011
Jammu and Kashmir, India
Tel: +91-194-240 34
E-mail: [email protected]
Received date: January 02, 2015; Accepted date: March 16 2015; Published date: March 24, 2015
Citation: Arif SH, Pandith AA, Bhat AR, Ramzan AU, Malik Nk,et al. (2015) EGFR and PTEN Gene Mutation Status in Glioblastoma Patients and their Prognostic Impact on Patient’s Survival. J Carcinog Mutagen 6:218. doi: 10.4172/2157-2518.1000218
Copyright: © 2015 Arif SH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Glioblastoma multiforme (GBM) is the most aggressive form of glioma. Genetic analysis of GBM tumorigenesis has identified several alterations in particular EGFR and PTEN genes. The purpose of the present study was to analyze the frequency and distribution of EGFR/PTEN mutations in GBM and to determine their relationship with different clinicopathological characteristics.
The paired tumor and adjacent normal tissue specimens of 40 consecutive patients with GBM were examined and DNA preparations were evaluated for the occurrence of EGFR/PTEN gene mutations by PCR-SCCP and DNA sequencing.
In total, 20 of 40 (50%) GBM tumours had mutation of either an EGFR or PTEN. EGFR gene mutation was present in 13 (32.5%) and PTEN gene mutations in 07 of 40 (17.5%) patients. Both EGFR/PTEN mutations were found in 03 of 40 samples (7.5%). The samples which showed EGFR mutations but were negative for PTEN were detected in 10 of 40 (25%) patients (EGFR+ve/PTEN-ve). The samples with PTEN +ve/EGFR –ve were present in 04 of 40 (10%) patients. Median PFS and Median OS was better in patients with EGFR +ve/PTEN -ve (p>0.05).
EGFR and PTEN gene mutations exist in our population with GBM and play a significant role in its development with better survival for patients for EGFR+ve/PTE –ve mutation status.